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Abstract 
Background: Tuberculosis elimination in low-incidence countries will require multip le 
interventions, including innovation in migrant screening. We examined a cohort of migrants 
screened pre-entry to England, Wales and Northern Ireland and identified tuberculosis after arrival. 
Methods: Migrants screened for active pulmonary tuberculosis pre-entry were linked to the 
Enhanced Tuberculosis Surveillance system. Primary outcomes were cases of notified tuberculos is 
(all forms) and bacteriologically confirmed pulmonary tuberculosis. Using molecular typing data, 
we identified assumed index cases leading to onward transmission and cases of tuberculos is 
assumed to be due to reactivation.  A cohort study was performed with incidence rates and risk 
factors estimated using Poisson regression. 
Findings: 519,955 migrants entered the cohort. The estimated incidence of all forms of 
tuberculosis in pre-entry screened migrants was 147 per 100,000 person years (95%CI:140-154). 
Radiographs compatible with active tuberculosis (but with negative pre-entry microbiologica l 
results) were at increased risk (Incidence rate ratio 3.2; 95%CI:2.8-3.7; p-value<0.001). Incidence 
of post migration tuberculosis increased with increasing WHO-estimated prevalence. 35/318,983 
of notified cases with typing data were assumed index cases.  Estimates of the rate of assumed 
reactivation tuberculosis ranged from 46 (95%CI:42-52) to 91 (95%CI:82-102). 
Interpretation: Pre-entry screened migrants from high incidence countries pose a negligible risk of 
onward transmission but have an ongoing increased risk of tuberculosis, which could potentially 
be prevented through identification and treatment of latent infection conducted in close 
collaboration with a pre-entry screening programme.   
Funding: Wellcome Trust, UK National Institute for Health Research, Medical Research Council 
and Public Health England. 
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Research in context 
Evidence before this study 
We updated our recent systematic review of pre-entry screening for tuberculosis to include new 
articles published up until 19th November 2015. We used our original search terms includ ing 
migrants, pre-entry screening, and standard terms for tuberculosis. The updated search was 
conducted in Medline and Embase. The prevalence of culture-confirmed cases detected pre-entry 
increased with prevalence in the country of origin, but we found little evidence of systematic 
follow up of migrants after arrival at a national level and no comprehensive studies includ ing 
molecular epidemiological data to examine reactivation and transmission after arrival.  
Added value of this study 
Our study systematically estimates the incidence and risk factors for all forms of tuberculosis and 
bacteriologically confirmed pulmonary tuberculosis (i.e., those cases that could transmit infect ion) 
in migrants screened pre-entry and notified after arrival in a low tuberculosis incidence country. 
Risk of active tuberculosis (all forms) diagnosed after arrival increased with incidence in the 
country of origin and was higher in migrants with chest radiographs compatible with active 
tuberculosis. Our analysis included comprehensive molecular typing data on culture confirmed 
cases since 2010 and found that migrants with chest radiographs compatible with active 
tuberculosis, but not subsequently diagnosed with tuberculosis pre-entry, were at increased risk of 
disease assumed to be due to reactivation. The incidence of assumed index cases was low, 
indicating that pre-entry screened migrants pose a negligible public health risk in terms of 
transmission. The introduction of culture testing on sputum samples to the pre-entry protocol was 
associated with a decreased risk of tuberculosis notification after migration, supporting recent 
changes by the UK and USA programmes.  
Implications of all the available evidence 
Pre-entry screened migrants have a continuing risk of developing tuberculosis, much of which 
could plausibly be prevented through identification and treatment of latent infection. Given that 
incidence peaks four years after arrival, migrants from high incidence countries could be included 
in a “catch-up” latent tuberculosis screening programme. Improved testing and treatment for latent 
infection could potentially mitigate some of the health impact of tuberculosis in migrant groups.  
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Introduction 
Several countries have achieved low tuberculosis incidence whilst having large migrant 
populations from high burden countries.1–3 In many of these countries a large proportion of cases 
now occur in individuals born outside the country.4,5 Achieving the goal of tuberculos is 
elimination in low tuberculosis incidence countries is expected to require multiple interventions, 
including, but not limited to innovation in migrant screening. 
A recent systematic review demonstrated that pre-entry screening of migrants prior to travel to 
low incidence countries detected the largest number of cases when performed in high tuberculos is 
incidence countries.6 One-off pre-entry screening for active tuberculosis in migrants will only 
detect disease prevalent at the time of screening. There is little linked data on incident tuberculos is 
after migration to low-incidence countries in pre-entry screened populations, and even less data 
on risk factors for subsequent development of disease in this screened population. Previous studies 
focus prevalent cases detected during pre-entry screening6, use national tuberculosis notifica t ion 
data alone with no linkage to pre-entry screening records7, or follow up of a selected cohort of 
individuals from a limited number countries or sub-nationally after arrival8–10.   Consequently, it 
is uncertain what is the most effective approach to reducing the disease burden in this group, 
including latent tuberculosis screening and treatment, active case finding, and improving 
healthcare access.  
A UK pilot programme of pre-entry screening was conducted in 15 countries from 2005, and 
subsequently rolled out to 101 countries (Figure 1).11 Our study uses data from this pilot to create 
the largest cohort to date of migrants screened for active tuberculosis prior to entering a low 
incidence country and generates the first direct national estimates of incidence post-migration and 
risk factors for subsequent development of disease. We used genotyping data to identify cases that 
were likely due to reactivation of imported latent infection rather than acquisition in England, 
Wales and Northern Ireland (EWNI), and identified index cases for clusters of disease, as well as 
ascertaining the characteristics of such cases. Our results should inform future improvements in 
screening and migrant health initiatives.  
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Methods 
Study design and setting  
A population-based cohort study in migrants to the UK screened pre-entry for active tuberculos is 
disease was undertaken. Screening occurred between 2005 and April 2012, and was conducted by 
the International Organisation for Migration (IOM) as part of a pilot pre-entry screening 
programme in 15 high incidence countries (Figure 1; Pre-entry pilot scheme countries were 
Bangladesh, Burkina Faso, Cambodia, Cote D'Ivoire, Eritrea, Ghana, Kenya, Laos, Niger, 
Pakistan, Somalia, Sudan, Tanzania, Thailand, and Togo).  
Participants and tuberculosis screening 
Visa applicants intending to stay in the UK for >6 months were screened for active tuberculosis.1 2  
Briefly,  applicants  ≥11 years of age had a standard chest radiograph, and all with radiologica l 
findings compatible with tuberculosis (Full details of classification provided in appendix, pages 1 
& 4 – Table 1 & 4) were required to undergo sputum testing for tuberculosis. Culture testing 
became a requirement at all sites from 2013 but was phased in gradually across sites from 2007. 
Applicants without radiographic changes compatible with tuberculosis, and those with changes 
but negative sputum smears and cultures were provided with medical clearance certifica tes. 
Applicants diagnosed with active tuberculosis in the country of origin were required to complete 
treatment before repeat screening. All visa applicants from the 15 pilot countries over the age of 
11 were included in this study. 
Primary and secondary outcomes 
Primary outcomes were cases of 1) all forms of tuberculosis (including clinically diagnosed cases), 
and 2) bacteriologically confirmed pulmonary tuberculosis. Definitions and cases for the primary 
outcomes were taken from Enhanced Tuberculosis Surveillance (ETS) system.13 ETS contains data 
on all tuberculosis cases notified in EWNI, including both microbiologically confirmed cases and 
clinically diagnosed cases being treated with a full course of anti-tuberculous medication. All cases 
of tuberculosis presented in this paper were therefore diagnosed after migration and not during the 
pre-entry screening process. Pre-entry diagnosed cases are described in our separate recent 
publication.11 A full UK dataset was used for this study, but data from Scotland did not contain 
personal identifiable information on cases. 
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Secondary outcomes were: 1) Cases assumed to be due to reactivation based on molecular typing 
data (subsequently referred to as assumed reactivation cases, or for simplicity reactivation cases) 
and 2) Cases assumed to have led to transmission in EWNI based on being the first tuberculos is 
case in a molecular strain typing cluster (subsequently referred to as assumed index cases, or for 
simplicity index cases).  Reactivation cases represent disease that is potentially preventable 
through treatment of latent infection in migrants, and index cases lead to transmission that is 
potentially preventable. Individuals classified as index cases and reactivation cases were culture 
confirmed and had Mycobacterial Interspersed Repetitive Units (MIRU) profiles with at least 23 
complete loci notified in ETS between 1st January 2010 (when strain-typing data began to be 
systematically collected) and 31st December 2013.14 The index cases were identified by recorded 
date of notification and had a unique 23 MIRU strain type compared to all previously notified 
cases, but shared their strain type with one or more subsequently notified cases, suggesting 
possible transmission. Reactivation cases were defined as all cases with a unique 23 MIRU strain 
type. No country of birth or geographic restrictions were placed on ETS data. All migrants 
screened by IOM between 1st January 2009 and 31st December 2012 were included in the analys is 
of secondary outcomes.  
Variables, data sources and probabilistic linkage 
A full description of the data sources of variables, methods of assessment, details of subgroups 
chosen for the analysis are presented in Appendix, page 3. A validated probabilistic linkage 
software program15 was used to identify active tuberculosis cases notified in EWNI in the migrant 
cohort by linking the IOM database of migrants screened pre-entry between 1st January 2006 and 
31st December 2012 to ETS notified cases between 1st January 2006 and 31st December 2013. 
Cases notified in EWNI within 90 days of the issue of a medical certificate of clearance were 
assumed to be prevalent (not incident) tuberculosis missed by pre-entry screening and are 
subsequently referred to as missed prevalent cases. These missed prevalent cases were excluded 
from incidence rate analyses. Duplicate records were removed based on a series of rules described 
in detail in Appendix, page 2. Personal identifiable information was not available for notificat ions 
in Scotland, so cases in migrants to Scotland could not be identified, hence a proportion of migrants 
given a medical certificate of clearance were set not to enter the study cohort. 
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Statistical analysis 
Individuals in our cohort were at risk of tuberculosis notification from the date of entry until the 
first of the following events: tuberculosis notification, death, emigration, or the end of the follow-
up period. Since data were unavailable to indicate emigration to Scotland, death, or emigrat ion 
outside UK, these events were accounted-for probabilistically by multiple imputation. Imputation 
models for migration to Scotland and dates of death and emigration out of the UK were used to 
create ten imputed datasets, each of which was analysed separately. Analyses of ten imputed 
datasets were combined using Rubin’s rules16 to account for uncertainty in the imputed 
information, further details provided in Appendix, page 4.  
Data on long-term international migration indicated that 7.3% of migrants entering the UK 
between 2006 and 2012 would reside in Scotland.17 Therefore, each imputation model randomly 
selected 92.7% of migrants issued with a medical certificate of clearance to enter the cohort as a 
resident in EWNI. The imputation model used 2009 mortality data for England and Wales for dates 
of death, and data on UK entry clearance visas, detailing length of stay by type of visa and year of 
issue, for emigration from the UK (see Appendix, pages 5-13, for full details).  
Each imputed dataset was analysed as follows. Univariable and multivariable Poisson regression 
models were used to identify risk factors for the primary and secondary outcomes. Multivariab le 
results were adjusted for clustering by individual to take account of repeated entries by migrants 
into the cohort (due to migrants entering, leaving, and entering again with a new visa). In a further 
analysis, data were stratified by years since entry to examine incidence over time. Results were 
presented as incidence per 100,000 person years, incidence rate ratios, 95% confidence interva ls 
and two-sided p-values.  
Several sensitivity analyses were undertaken to examine the rules used in the imputat ion, 
deduplication, time period used for the definition of prevalent cases, and time period used for strain 
typing data. To create a crude upper bound of reactivation incidence we assumed that the 
proportion of cases with a unique strain type in untyped cases was similar to that in typed cases. 
These sensitivity analyses and the results are described in full in Appendix pages 13-21. Stata v.13 
(Statacorp LP, College Station, TX, USA) was used for all statistical analyses.  
Ethics approval 
Ethical approval was received for this analysis from UCL research ethics committee (3294/002). 
Data were stored and analysed at Public Health England which has authority under the Health and 
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Social Care Act 2012 to hold and analyse national surveillance data (including tuberculosis pre-
entry screening programme data) for public health and research purposes. 
Results 
Between 2006 and 2012 there were 640,808 visa applicants screened pre-entry by the IOM 
programme (Figure 2), whose records were probabilistically matched to ETS to identify 
tuberculosis cases with dates of illness onset in the years 2006 to 2013. After excluding duplicates 
(79,331), and missed prevalent cases (41) there were 561,436 migrants. Assuming 7.3% of 
migrants moved to Scotland, there were 519,955 entries into the study cohort between 2006-2012, 
representing 514,968 individual migrants.  
The total length of follow up for the cohort was 1,275,569 person years with a mean follow up of 
2.45 years per person. There were 41 missed prevalent cases identified in the 90 days after 
migration, 36.6% (15/41) of whom had pre-entry chest radiographs compatible with active 
tuberculosis; all 41 were excluded from further analyses. There were 1,873 incident cases of all 
forms of tuberculosis identified (diagnosed after migration), a crude incidence rate of 147 per 
100,000 person years (95%CI:140-154; Table 1).  
In a multivariable risk factor analysis adjusted for age and sex there was strong evidence that self-
report of close or household contact with a case of tuberculosis (Incidence Rate Ratio (IRR) 3.0; 
95%CI:1.8-5.1; p-value<0.001) and screening chest radiographs compatible with active 
tuberculosis but with negative microbiology results at the time of screening (IRR 3.2; 95%CI:2.8-
3.7; p-value<0.001) were associated with increased risk of tuberculosis notified in EWNI. There 
was also strong evidence that migrants from countries with WHO-estimated prevalence of 40-149 
per 100,000 (IRR 0.3; 95%CI:0.2-0.4; p-value<0.001), and 150-349 (IRR 0.6; 95%CI:0.5-0.6; p-
value<0.001) were at lower risk compared to migrants from countries with a prevalence >350. 
Visa category was also important, with settlement and dependant visas associated with lower risk 
(IRR 0.8; 95%CI:0.7-0.9; p-value<0.001), and family reunion visas associated with elevated risk 
(IRR 2.6; 95%CI:1.9-3.5; p-value<0.001) compared to student visas. Finally, there was evidence 
that being screened at a site where culture testing of sputa had been introduced was associated with 
a lower risk of tuberculosis after entry to EWNI (IRR 0.9; 95%CI:0.8-1.0; p-value=0.003). 
Considering all cases of tuberculosis detected both pre-entry and after migration, the majority were 
incident cases notified in EWNI (1873; 79.6%), with fewer pre-entry prevalent cases (439 detected 
between 2006-2012; 18.7%), and a small number of post-entry missed prevalent cases (41 cases 
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notified 90 days post migration; 1.7%; Figure 3a). The total number of cases in migrants declined 
by years since migration when including prevalent cases detected at pre-entry screening (and not 
entering the cohort as they were declined medical certificates of clearance) and post-entry missed-
prevalent cases.The majority of cases detected in the first year after migration were these prevalent 
cases. Accounting for person time at risk within the cohort (and excluding pre- and post-entry 
prevalent cases) the incidence of all forms of tuberculosis was lowest in the first 12 months after 
migration (61 per 100,000 person years; 95%CI:54-69), peaked in the fourth year (222; 
95%CI:198-249) and then gradually declined (Figure 3b).  
Reactivation and index cases.   
There were a total of 648,385 person years within the cohort used to examine assumed reactivat ion 
and index cases. 60.0% of notified cases of disease in this cohort were culture confirmed and 
84.8% had strain typing results available. There were 301 cases of assumed reactivation with crude 
estimated incidence of 46 per 100,000 person years (95%CI:42-52; Table 2). A crude upper bound 
of reactivation assuming that the proportion of cases with a unique strain type in untyped cases 
was similar to that in typed cases provided an estimate of 91 per 100,000 person years (95%CI:82-
102). After adjusting for age and sex, there was evidence that compared with migrants from 
countries with a prevalence greater than 350 per 100,000, those from countries with a prevalence 
of 40-149 were at lower risk of reactivation (IRR 0.2; 95%CI:0.1-0.9; p-value 0.034) as were those 
from countries with a prevalence of 150-349 (IRR 0.3; 95%CI:0.2-0.6; p-value<0.001). There was 
also strong evidence that migrants with a chest radiograph classified as compatible with 
tuberculosis (but not bacteriologically confirmed at the time of screening) were at increased risk 
of reactivation (IRR 3.9; 95%CI:2.7-5.5; p-value<0.001).  
There were 35 migrants who were assumed index cases for onward transmission, providing an 
estimated crude rate of 5 per 100,000 person years (95%CI:4-8). The crude incidence rate for index 
cases was highest in those with chest radiographs suggestive of active tuberculosis but with 
negative bacteriology at the time of screening (36; 95%CI:19-68), and this group had increased 
risk (IRR 9.6; 95%CI:4.4-20.7; p-value<0.001) compared to those with no abnormalities after 
adjusting for age and sex.  
The results of these analyses were stable across a range of sensitivity analyses undertaken to test 
the data and key assumptions in the imputation - full results are presented and discussed in the 
Appendix pages 15-21.  
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Discussion 
Our cohort analysis presents data on just over half a million migrants screened for tuberculos is 
from 15 high incidence countries between 2006 and 2012. There was evidence that a chest 
radiographs classified as compatible with active tuberculosis (but not subsequently diagnosed as 
tuberculosis pre-entry) and individuals reporting a history of close or household contact with a 
case of tuberculosis prior to migration were associated with increased risk of tuberculosis (all 
forms), bacteriologically confirmed pulmonary disease, assumed reactivation and assumed index 
cases. Migrants screened at locations where sputum samples underwent culture testing had a lower 
risk after arrival in EWNI compared to those who were not. Incidence of all forms of tuberculos is 
were lowest in the first year after arrival and peaked in the fourth, before gradually declining, 
although confidence intervals for estimates in later years were wider due to decreasing cohort size. 
Rates of assumed index cases were low, with only 35 identified in total.  Our data suggest that pre-
entry screened migrants pose a negligible risk in terms of onwards transmission within the host 
country, but their individual risk remained increased presenting an ongoing risk to their own 
health. 
All visa applicants from the 15 countries taking part in the pre-entry screening pilot between 2006-
2012 were included in this analysis. The results are therefore highly representative of migrants 
from these locations applying to stay for 6 months or longer. We were able to identify migrants 
screened pre-entry, and not just those self-reporting birth outside the UK and as a result we provide 
the first national estimates and risk factors for incident tuberculosis in migrants screened for 
tuberculosis pre-entry. The large study size and follow up time minimize statistical chance as an 
alternative explanation for the majority of findings. We also provide the first national description 
of strain typing data in migrants screened for active tuberculosis in pre-entry programme, based 
upon MIRU VNTR. Compared to Restriction Fragment Length Polymorphism (RFLP), MIRU 
VNTR does not require large quantities of DNA from patients as it is a PCR-based method, and 
therefore is also quicker, and provides a result that can be digitised and exchanged between 
national tuberculosis control programmes more easily. Spoligotyping, another PCR-based method, 
has less discriminatory power than RFLP, whereas MIRU VNTR has been shown to have 
equivalent or improved power to RFLP. Additionally, MIRU VNTR is now used by a majority of 
national to control programmes that conduct routine molecular testing of cases.18 
Some limitations should be considered. The data are highly representative of migrants to the UK 
intending to stay for >6 months, but do not cover those intending shorter stays, or undocumented 
migrants and asylum seekers19 However, whilst undocumented migrants and asylum seekers are a 
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particularly vulnerable group, their comparatively small numbers mean they account for low 
numbers of notified cases.  
A number of risk factors for tuberculosis were included in this analysis, but no data were availab le 
for socio-economic status, relevant clinical conditions (such as HIV) or lifestyle and behavioura l 
risk factors such as smoking, problem drug and alcohol use, and history of imprisonment, all of 
which are associated with an increased risk of tuberculosis in the UK.20–26  
Whilst there is a high level of certainty that individuals receiving a visa for entry into the UK do 
migrate27–29, there is less certainty about when and whether these same individuals leave after their 
visa expires. We account for the uncertain duration of stay and death rates through imputat ion 
based on visa length data and national death rates. Several sensitivity analyses examining the 
impact of these assumptions were stable and therefore provide reassurance that these data and 
results are robust.  
Assumed reactivation and index cases were those representing the first appearance of a strain type 
during the study period. There are several important limitations with the strain typing data used in 
this analysis. Firstly, only 60.0% of notified cases were culture confirmed and 84.8% of these had 
strain typing results in the UK; cases without a strain type did not have an opportunity to be 
classified using this approach. Many of the cases not culture confirmed would also likely be due 
to reactivation. As a result, there will be under ascertainment of assumed reactivation cases, 
making the estimates presented here lower bounds of true rates, although our estimated upper 
bound provides a likely ceiling to this estimate.25 Secondly, assumed index cases might have been 
underestimated because a unique strain may be involved in a cluster with another case that has not 
yet been reported. The sensitivity analysis examining clustering by time period provides some 
confidence that within this dataset, which has four years of data, this issue should be minimal. 
Thirdly, whole genome sequencing has shown that MIRU VNTR strain typing does not provide a 
very high level of resolution, and that cases with identical MIRU VNTR strain types may in fact 
not be part of the same transmission chain,30 which would lead to an overestimate in the number 
of index cases and further under estimation of the number of reactivation cases. Again, this is 
likely to have only a small impact on index case rates.30–33 Overall, we believe that the direction 
of bias as a result of these limitations is that the incidence estimates for reactivation presented here 
are probably lower estimates of true values, and the magnitude of bias in assumed index cases is 
expected to be small. 
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Among those screened pre-entry there are several groups at higher risk of tuberculosis after 
migration, including those on family reunion visas, those from high incidence countries, those with 
positive chest radiograph findings and those reporting close or household contact with a case of 
tuberculosis prior to migration. For these groups, efforts should be made to facilitate accessing 
health services, including access to latent tuberculosis screening, to reduce risks of poorer health 
outcomes and transmission to others. Improved integration of pre-entry screening programmes and 
health services in the destination country will benefit migrants and local populations and improve 
targeted post-entry latent tuberculosis screening efforts. A cost-effective analysis should also be 
undertaken for active pre-entry screening using these data, combined with that from previous 
studies, and used to help refine the targeting screening programmes further.6,11  
Our study supports continuing pre-entry radiographic screening with culture based investiga t ion 
of those with films consistent with tuberculosis.  Screening for latent infection could be targeted 
at those from high incidence countries and those with chest radiographs compatible with active 
tuberculosis but negative bacteriology on initial screening. Latent tuberculosis infection screening 
could be conducted alongside pre-entry screening or post migration.  Uptake of latent tuberculos is 
infection screening is likely to be higher if done alongside pre-entry screening, but up-take of 
treatment may be higher if screening is done post-migration when migrants are linked into health 
services. Given that incidence peaks at 4 years after arrival, those from very high incidence 
countries who have migrated in the last 5 years might be targeted in a "catch-up" programme.  
Latent tuberculosis infection screening programmes should be evaluated, their cost-effectiveness 
investigated and delivery models adapted in light of such evaluations.  The data linkage approach 
we have developed could be used to support such evaluations as well as to investigate broader 
health issues in migrant populations. 
The fact that only 35 out of more than three hundred thousand pre-entry screened migrants were 
identified as an assumed index cases suggests that following screening migrants pose a negligib le 
public health risk in terms of transmission. Nevertheless pre-entry screened migrants have a 
continuing risk of developing tuberculosis, much of which could plausibly be prevented through 
identification and treatment of latent infection with appropriate prioritisation of those with baseline 
chest radiographs suggestive of active tuberculosis (and no microbiological confirmation).  This 
could potentially mitigate the health impact of tuberculosis in migrant groups. Our study provides 
the basis for several evidence-based improvements to pre-entry screening of migrants, which if 
implemented should contribute towards the target of tuberculosis elimination in low-incidence 
countries and improving the health of migrants. 
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Tables 
Table 1. Baseline characteristics, univariate and multivariate analysis of incidence rates for tuberculosis (all forms including clinically diagnosed 
cases) and bacteriological confirmed pulmonary tuberculosis in migrants screened pre-entry (2006-2012) and notified in ETS (2006-
2013)  
    All notif ied cases of tuberculosis   Bacteriological confirmed pulmonary tuberculosis 
Risk Factor 
Migrants 
contributing (%) 
Rate per 100,000 
person years (95% CI)  
Univariable 
IRR (95% CI) 
Multivariable 
IRR (95%CI) 
p-value   
Rate per 100,000 
person years (95% CI)  
Univariable 
IRR (95% CI) 
Multivariable 
IRR (95%CI) 
p-value 
                     
All 519955 (100%)  147 (140, 154) - - -   49 (45, 53) - - - 
                      
Age                      
0-15 15468 (3.0%) 101 (77, 132) 0.7 (0.5, 0.9) 0.8 (0.6, 1.0) 0.057   37 (24, 58) 0.7 (0.5, 1.2) 0.9 (0.6, 1.4) 0.677 
16-44 490806 (94.4%) 149 (142, 156) 1.0 1.0     50 (46, 54) 1.0 1.0   
45-64 11243 (2.2%) 146 (111, 193) 1.0 (0.7, 1.3) 1.0 (0.8, 1.3) 0.941   35 (20, 62) 0.7 (0.4, 1.2) 0.7 (0.4, 1.3) 0.271 
65+ 2438 (0.5%) 210 (127, 347) 1.5 (0.9, 2.5) 1.1 (0.7, 2.0) 0.615   92 (43, 194) 2.1 (1.0, 4.6) 1.7 (0.7, 3.8) 0.232 
                      
Sex                     
Female 173116 (33.3%) 133 (123, 143) 1.0 1.0     45 (39, 51) 1.0 1.0   
Male 346839 (66.7%) 157 (149, 167) 1.2 (1.1, 1.3) 1.0 (0.9, 1.1) 0.533   52 (47, 58) 1.2 (1.0, 1.4) 0.9 (0.8, 1.1) 0.357 
                      
Close or household 
contact w ith a case of 
TB                     
No 518735 (99.8%) 146 (140, 153) 1.0       49 (45, 53) 1.0 1.0   
Yes 1220 (0.2%) 463 (279, 770) 3.1 (1.9, 5.2) 3.0 (1.8, 5.1) <0.001   278 (144, 535) 5.7 (2.9, 11.0) 5.0 (2.6, 9.7) <0.001 
                      
Visa                     
Students 307127 (59.1%) 161 (151, 172) 1.0 1.0     58 (52, 64) 1.0 1.0   
19 
Settlement and 
Dependents 159986 (30.8%) 128 (119, 137) 0.8 (0.7, 0.9) 0.8 (0.7, 0.9) <0.001   41 (37, 47) 0.7 (0.6, 0.9) 0.7 (0.6, 0.8) <0.001 
Work 21140 (4.1%) 174 (139, 218) 1.1 (0.9, 1.4) 1.0 (0.8, 1.3) 0.722   53 (35, 79) 0.9 (0.6, 1.4) 0.9 (0.6, 1.3) 0.559 
Working Holiday 
Maker 17526 (3.4%) 146 (94, 226) 0.9 (0.6, 1.4) 1.1 (0.7, 1.7) 0.675   15 (4, 58) 0.3 (0.1, 1.0) 0.3 (0.1, 1.2) 0.083 
Family Reunion 3989 (0.8%) 320 (244, 419) 2.0 (1.5, 2.6) 2.6 (1.9, 3.5) <0.001   72 (41, 128) 1.3 (0.7, 2.2) 1.4 (0.8, 2.6) 0.227 
Other 10187 (2%) 124 (81, 191) 0.8 (0.5, 1.2) 1.2 (0.8, 1.9) 0.373   41 (20, 87) 0.7 (0.3, 1.5) 1.0 (0.5, 2.2) 0.941 
                      
CXR                     
No abnormality 489733 (94.2%) 135 (129, 142) 1.0 1.0     43 (40, 47) 1.0 1.0   
Compatible w ith TB 21862 (4.2%) 426 (375, 484) 3.2 (2.8, 3.6) 3.2 (2.8, 3.7) <0.001   177 (146, 216) 4.1 (3.3, 5.1) 4.2 (3.4, 5.3) <0.001 
Abnormality not TB 8360 (1.6%) 82 (52, 130) 0.6 (0.4, 1.0) 0.8 (0.5, 1.3) 0.455   27 (12, 61) 0.6 (0.3, 1.4) 0.8 (0.4, 1.9) 0.624 
                      
WHO category                     
40-149 29143 (5.6%) 40 (27, 60) 0.2 (0.2, 0.4) 0.3 (0.2, 0.4) <0.001   17 (9, 31) 0.3 (0.2, 0.6) 0.4 (0.2, 0.7) 0.002 
150-349 75294 (14.5%) 107 (94, 122) 0.7 (0.6, 0.8) 0.6 (0.5, 0.6) <0.001   40 (32, 49) 0.8 (0.6, 1.0) 0.6 (0.5, 0.8) <0.001 
350+ 415518 (79.9%) 162 (154, 170) 1.0 1.0     53 (49, 58) 1.0 1.0   
                      
Sputum culture testing                   
No 179935 (34.6%) 152 (143, 163) 1.0 1.0     50 (44, 56) 1.0 1.0   
Yes 340020 (65.4%) 143 (134, 152) 0.9 (0.8, 1.0) 0.9 (0.8, 1.0) 0.003   49 (44, 54) 1.0 (0.8, 1.2) 0.9 (0.8, 1.0) 0.152 
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Table 2. Baseline characteristics, univariable and multivariate analysis of incidence rates for assumed reactivation and assumed index cases of 
tuberculosis in migrants screened pre-entry (2009-2012) and notified in ETS (2010-2013) 
    Assumed reactivation   Assumed index cases 
Risk Factor 
Migrants 
contributing (%) 
Rate per 
100,000 person 
years (95% CI)  
Univariable IRR 
(95% CI) 
Multivariable 
IRR (95%CI) 
p-value   
Rate per 
100,000 
person years 
(95% CI)  
Univariable IRR 
(95% CI) 
Multivariable IRR 
(95%CI) 
p-value 
                     
All 318983 (100%) 46 (42, 52)         5 (4, 8)       
                      
Age                      
0-15 9542 (3.0%) 12 (4, 38) 0.3 (0.1, 0.8) 0.4 (0.1, 1.1) 0.073   4 (1, 29) 0.7 (0.1, 5.4) 1.2 (0.2, 8.5) 0.845 
16-44 301358 (94.5%) 48 (43, 54) 1.0 1.0     6 (4, 8) 1.0 1.0   
45-64 6466 (2.0%) 33 (14, 79) 0.7 (0.3, 1.6) 0.9 (0.4, 2.3) 0.868   -       
65+ 1617 (0.5%) 26 (4, 185) 0.5 (0.1, 3.9) 0.5 (0.1, 3.7) 0.498   -       
                      
Sex                     
Female 101715 (31.9%) 33 (27, 41) 1.0 1.0     3 (1, 6) 1.0     
Male 217268 (68.1%) 54 (47, 62) 1.6 (1.3, 2.1) 1.1 (0.8, 1.5) 0.47   7 (5, 10) 2.8 (1.1, 6.7) 1.9 (0.8, 4.6) 0.14 
                      
Close or household 
contact w ith a case of 
TB                     
No 318126 (99.7%) 46 (41, 52) 1.0 1.0     5 (4, 8)       
Yes 857 (0.3%) 55 (8, 394) 1.2 (0.2, 8.5) 1.3 (0.2, 9.2) 0.803   -     
                      
Visa                     
Students 206142 (64.6%) 58 (50, 66) 1.0 1.0     7 (5, 10) 1.0     
Settlement and 
Dependents 94118 (29.5%) 32 (26, 40) 0.6 (0.4, 0.7) 0.7 (0.5, 0.9) 0.012   4 (2, 7) 0.5 (0.2, 1.1) 0.8 (0.4, 1.8) 0.581 
Work 10578 (3.3%) 31 (14, 69) 0.5 (0.2, 1.2) 0.6 (0.3, 1.2) 0.147   5 (1, 37) 0.8 (0.1, 5.6) 0.9 (0.1, 5.6) 0.871 
Working Holiday 
Maker 861 (0.3%) -      -     
Family Reunion 2335 (0.7%) 73 (31, 176) 1.3 (0.5, 3.1) 3.1 (1.3, 7.6) 0.013   -     
21 
Other 4949 (1.6%) -      -     
                      
CXR                     
No abnormality 302364 (94.8%) 43 (38, 48) 1.0 1.0     4 (3, 6) 1.0     
Compatible w ith TB 12304 (3.9%) 154 (113, 211) 3.6 (2.6, 5.1) 3.9 (2.7, 5.5) <0.001   36 (19, 68) 8.4 (3.9, 17.9) 9.6 (4.4, 20.7) <0.001 
Abnormality not TB 4315 (1.4%) 11 (2, 77) 0.3 (0.0, 1.8) 0.5 (0.1, 3.7) 0.52   -       
                      
WHO category                     
40-149 12402 (3.9%) 8 (2, 30) 0.1 (0.0, 0.6) 0.2 (0.1, 0.9) 0.034   4 (1, 27) 0.6 (0.1, 4.5) 1.2 (0.2, 7.8) 0.876 
150-349 39287 (12.3%) 19 (12, 31) 0.4 (0.2, 0.6) 0.3 (0.2, 0.6) <0.001   1 (0, 8) 0.2 (0.0, 1.4) 0.2 (0.0, 1.6) 0.144 
350+ 267294 (83.8%) 53 (47, 59) 1.0 1.0     6 (4, 9) 1.0 1.0   
                      
Sputum culture testing                   
No 11570 (3.6%) 39 (23, 65) 1.0 1.0     3 (0, 20) 1.0 1.0   
Yes 307413 (96.4%) 47 (42, 53) 1.2 (0.7, 2.1) 1.1 (0.6, 1.9) 0.728   6 (4, 8) 2.0 (0.3, 14.7) 1.7 (0.3, 11.0) 0.596 
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Figures 
 
Figure 1. Location of pre-entry screening sites globally (includes IOM and non-IOM 
sites).  
 Note: Pre-entry pilot scheme countries were Bangladesh, Burkina Faso, Cambodia, 
Cote D'Ivoire, Eritrea, Ghana, Kenya, Laos, Niger, Pakistan, Somalia, Sudan, 
Tanzania, Thailand, and Togo. 
 
  
Figure 2. Study participant flow diagram 
 *Numbers assumed to migrate to Scotland varied by imputation, and sum of those 
excluded does not equal difference between total visa applicants and the number of 
migrants included in final cohort, as groups are not mutually exclusive. 
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Figure 3. Tuberculosis examined by years since migration: A) Pre-entry prevalent cases 
(439 detected between 2006-2012), post-entry missed prevalent cases (41 cases 
notified 90 days post migration) and all tuberculosis cases (1873 cases) 
notified in the UK among migrant by year since migration. B) Incidence rates 
for tuberculosis (all types) by time since entry 
   
 
